Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Serge Gauthier

Showing results (361-370 of 370) with videos related to

Pageof 37
Sort By:
You have reached the last page of results.This site can display upto 370 results.
JAMA Neurology|April 29, 2024
Downstream Biomarker Effects of Gantenerumab or Solanezumab in Dominantly Inherited Alzheimer Disease: The DIAN-TU-001 Randomized Clinical TrialOlivia Wagemann, Haiyan Liu, Guoqiao Wang, et al.
European Journal of Nuclear Medicine and Molecular Imaging|April 5, 2023
Longitudinal head-to-head comparison of <sup>11</sup>C-PiB and <sup>18</sup>F-florbetapir PET in a Phase 2/3 clinical trial of anti-amyloid-β monoclonal antibodies in dominantly inherited Alzheimer's diseaseCharles D Chen, Austin McCullough, Brian Gordon, et al.
Alzheimer'S & Dementia : the Journal of the Alzheimer'S Association|July 15, 2025
Regional effects of gantenerumab on neuroimaging biomarkers in the DIAN-TU-001 trialAustin McCullough, Charles D Chen, Brian A Gordon, et al.
Nature Aging|November 12, 2024
Diagnosis of Alzheimer's disease using plasma biomarkers adjusted to clinical probabilityJoseph Therriault, Shorena Janelidze, Andréa Lessa Benedet, et al.
Annals of Neurology|September 24, 2022
Amyloid-Related Imaging Abnormalities in the DIAN-TU-001 Trial of Gantenerumab and Solanezumab: Lessons from a Trial in Dominantly Inherited Alzheimer DiseaseNelly Joseph-Mathurin, Jorge J Llibre-Guerra, Yan Li, et al.
JAMA Neurology|September 16, 2025
Revised Diagnostic Criteria for Vascular Cognitive Impairment and Dementia-The VasCog-2-WSO Criteria, Perminder S Sachdev, Adam C Bentvelzen, et al.
The Lancet. Neurology|March 22, 2025
Safety and efficacy of long-term gantenerumab treatment in dominantly inherited Alzheimer's disease: an open-label extension of the phase 2/3 multicentre, randomised, double-blind, placebo-controlled platform DIAN-TU trialRandall J Bateman, Yan Li, Eric M McDade, et al.
Journal of Alzheimer'S Disease : JAD|December 5, 2024
Impact of a national dementia research consortium: The Canadian Consortium on Neurodegeneration in Aging (CCNA)Howard Chertkow, Natalie Phillips, Kenneth Rockwood, et al.
Nature Medicine|June 22, 2021
A trial of gantenerumab or solanezumab in dominantly inherited Alzheimer's diseaseStephen Salloway, Martin Farlow, Eric McDade, et al.
Medrxiv : the Preprint Server for Health Sciences|February 20, 2025
Safety and efficacy of long-term gantenerumab treatment in dominantly inherited Alzheimer's disease: an open label extension of the phase 2/3 multicentre, randomised, double-blind, placebo-controlled platform DIAN-TU TrialRandall J Bateman, Yan Li, Eric M McDade, et al.
Pageof 37

Showing results (361-370 of 370) with videos related to

Sort By:
Pageof 37
You have reached the last page of results.This site can display upto 370 results.
JAMA Neurology|April 29, 2024
Downstream Biomarker Effects of Gantenerumab or Solanezumab in Dominantly Inherited Alzheimer Disease: The DIAN-TU-001 Randomized Clinical TrialOlivia Wagemann, Haiyan Liu, Guoqiao Wang, et al.
European Journal of Nuclear Medicine and Molecular Imaging|April 5, 2023
Longitudinal head-to-head comparison of <sup>11</sup>C-PiB and <sup>18</sup>F-florbetapir PET in a Phase 2/3 clinical trial of anti-amyloid-β monoclonal antibodies in dominantly inherited Alzheimer's diseaseCharles D Chen, Austin McCullough, Brian Gordon, et al.
Alzheimer'S & Dementia : the Journal of the Alzheimer'S Association|July 15, 2025
Regional effects of gantenerumab on neuroimaging biomarkers in the DIAN-TU-001 trialAustin McCullough, Charles D Chen, Brian A Gordon, et al.
Nature Aging|November 12, 2024
Diagnosis of Alzheimer's disease using plasma biomarkers adjusted to clinical probabilityJoseph Therriault, Shorena Janelidze, Andréa Lessa Benedet, et al.
Annals of Neurology|September 24, 2022
Amyloid-Related Imaging Abnormalities in the DIAN-TU-001 Trial of Gantenerumab and Solanezumab: Lessons from a Trial in Dominantly Inherited Alzheimer DiseaseNelly Joseph-Mathurin, Jorge J Llibre-Guerra, Yan Li, et al.
JAMA Neurology|September 16, 2025
Revised Diagnostic Criteria for Vascular Cognitive Impairment and Dementia-The VasCog-2-WSO Criteria, Perminder S Sachdev, Adam C Bentvelzen, et al.
The Lancet. Neurology|March 22, 2025
Safety and efficacy of long-term gantenerumab treatment in dominantly inherited Alzheimer's disease: an open-label extension of the phase 2/3 multicentre, randomised, double-blind, placebo-controlled platform DIAN-TU trialRandall J Bateman, Yan Li, Eric M McDade, et al.
Journal of Alzheimer'S Disease : JAD|December 5, 2024
Impact of a national dementia research consortium: The Canadian Consortium on Neurodegeneration in Aging (CCNA)Howard Chertkow, Natalie Phillips, Kenneth Rockwood, et al.
Nature Medicine|June 22, 2021
A trial of gantenerumab or solanezumab in dominantly inherited Alzheimer's diseaseStephen Salloway, Martin Farlow, Eric McDade, et al.
Medrxiv : the Preprint Server for Health Sciences|February 20, 2025
Safety and efficacy of long-term gantenerumab treatment in dominantly inherited Alzheimer's disease: an open label extension of the phase 2/3 multicentre, randomised, double-blind, placebo-controlled platform DIAN-TU TrialRandall J Bateman, Yan Li, Eric M McDade, et al.
Pageof 37